Medicare drug-plan season is approaching, and the first national numbers for 2027 are already on the table. They are useful, but they are also easy to misuse.
CMS says the 2027 national base beneficiary premium for Part D will be $41.33. The national average monthly bid amount will be $296.05. Those figures help determine how the Part D system is financed, but neither is a quote for the premium an individual beneficiary will pay. CMS says the finalized 2027 Medicare Advantage and Part D landscape, including final average premiums and plan offerings, will be released in mid-to-late September.
That gap between national benchmarks and plan-level prices creates a practical August decision point for households approaching or already in Medicare. There is enough information to prepare for 2027, but not enough to make a sound plan-selection decision yet.
The right task now is not to guess which plan will win. It is to build the comparison file you will need when the actual landscape appears: your current prescriptions, doses, preferred pharmacies, expected high-cost fills, current plan notices and the amount of monthly cash-flow flexibility you want.
What CMS has already told us
The national base beneficiary premium is a statutory starting point used in Part D premium calculations. For 2027, CMS set it at $41.33. That is up from the 2026 national base beneficiary premium of $38.99. The law limits annual growth in this base figure through 2029, but an individual plan premium can still differ substantially because plan bids, supplemental coverage, geography and other factors affect what members ultimately pay.
CMS also set the 2027 national average monthly bid amount at $296.05. This is an enrollment-weighted average of plan bids for basic Part D benefits and is used in calculating the government subsidy. It is not the monthly bill a beneficiary should expect to receive.
The standard benefit parameters are changing too. CMS materials for 2027 show the standard Part D deductible rising from $615 in 2026 to $700 in 2027. The annual out-of-pocket threshold for covered Part D drugs rises from $2,100 to $2,400. Once a beneficiary reaches the catastrophic phase, there is no additional out-of-pocket cost sharing for covered Part D drugs under the redesigned benefit.
These national figures are useful for budgeting ranges. They are not enough to answer the question most households actually care about: what will my prescriptions cost under my available plans next year?
Why the premium alone can mislead
A lower premium can coexist with higher total drug spending. Formularies differ. A drug can move between tiers. Coinsurance can matter more than a fixed copay for an expensive medication. A preferred pharmacy can be materially cheaper than another in-network pharmacy, while an out-of-network pharmacy may require paying the full cost and seeking partial reimbursement later.
That is why Medicare itself directs beneficiaries to look beyond the monthly premium. The combination of premium, deductible, drug-specific cost sharing, formulary coverage and pharmacy network determines the household result.
For a person taking several inexpensive generics, the premium may be a large share of annual Part D spending. For someone using a specialty drug, the timing and structure of cost sharing can dominate the premium. Two households can therefore look at the same $41.33 national base premium and have completely different planning problems.
The cash-flow question is separate from the cost question
Medicare’s Prescription Payment Plan can spread covered Part D out-of-pocket costs across the calendar year. Medicare is explicit that the option does not reduce drug costs. It changes when those costs are paid.
That distinction matters because the program becomes less useful as the year progresses. Medicare notes that it tends to be most helpful when participation begins early in the year and significant drug costs occur early. New fills later in the year leave fewer months over which to spread remaining payments.
For 2027 planning, that means beneficiaries with predictable high early-year prescription costs should treat payment timing as a separate comparison item. First estimate total annual plan cost. Then decide whether smoothing those costs across monthly bills would make household cash flow easier to manage.
A four-part file to prepare before September
First, build a current medication list. Include the exact drug name, dosage, quantity and refill frequency. Do not rely on a memory-based list assembled while comparing plans. A small difference in formulation or dose can change a formulary search.
Second, identify the pharmacies you are realistically willing to use. Medicare notes that preferred in-network pharmacies may have lower cost sharing than other in-network pharmacies. Mail order may also be available for longer supplies. If convenience matters, put a value on it rather than automatically choosing the lowest displayed price.
Third, save your current plan’s annual notice of change when it arrives. Compare what is changing in the plan you already have before deciding whether inertia is harmless. Premium changes are only one line. Formulary, tier, pharmacy and utilization-management changes can be more important.
Fourth, mark the prescriptions that drive most of your spending. Those drugs deserve the closest comparison. If one medicine accounts for most annual out-of-pocket expense, a plan that treats that drug favorably can outweigh a modest premium difference.
The decision test when the landscape arrives
When CMS and Medicare publish finalized plan choices, compare plans using the same sequence for each option.
Start with whether every important drug is covered. Then check restrictions such as prior authorization, quantity limits or step therapy. Next compare the cost at pharmacies you would actually use. Add the annual premium and expected deductible exposure. Finally, examine how quickly your expected spending could approach the $2,400 2027 out-of-pocket threshold.
This produces a more useful figure than premium alone: estimated annual household cost under realistic behavior.
For couples, run the analysis separately. Medicare Part D coverage is individual, and spouses can have different medications, pharmacies and plan economics. A plan that is efficient for one spouse is not automatically efficient for the other.
Do not confuse the base premium with your future bill
The $41.33 figure will appear in many 2027 Medicare discussions because it is a clean national number. Its role is real, but limited. It is a base beneficiary premium used in the Part D framework. Actual plan premiums are plan-specific.
The same caution applies to the $296.05 national average monthly bid amount. It tells us something about the financing environment facing the Part D program, not what a beneficiary should put into a household budget as a monthly premium.
CMS has already said the more actionable information comes later: the finalized plan landscape and final average premiums in September. Until then, precise claims about an individual’s 2027 premium are premature.
What would change the view
The planning approach would change if CMS materially revises the published 2027 parameters, if a beneficiary qualifies for Extra Help, or if a major medication changes before enrollment decisions are made. Extra Help can reduce premiums, deductibles and cost sharing for qualifying people, so standard benefit parameters may not describe their actual exposure.
The analysis also changes when an employer or retiree plan provides creditable drug coverage. In that case, the relevant comparison is not simply among standalone Part D plans. The employer coverage rules and consequences of leaving that coverage need to be understood first.
Finally, a new diagnosis or high-cost prescription can make a previously minor formulary detail central. Plan shopping should use the medication list expected for the coming year, not just a backward-looking total from the current year.
The useful move before open enrollment
There is no advantage in pretending the plan-level data are available before they are. There is an advantage in being ready when they arrive.
Use the national 2027 numbers as boundary markers: a $41.33 base beneficiary premium, a $700 standard deductible and a $2,400 standard out-of-pocket threshold. Then wait for the actual plan landscape before drawing conclusions about your own premium or total cost.
In the meantime, assemble the drug list, pharmacy preferences, current-plan notice and high-cost prescription schedule. That turns September’s flood of plan information into a structured household decision instead of a last-minute search.
The key question for 2027 is not whether the national base premium went up. It is whether the plan you choose covers the medicines you actually use, at the pharmacies you will actually visit, with a total annual cost and payment pattern your household can absorb.
Jasper Kellan is editor of The Perspective Log. This article is general information, not personal investment, tax or legal advice. Published August 31, 2026.
Primary sources: CMS — Medicare Part D 2027 National Average Monthly Bid Amount Information; CMS — 2027 Medicare Advantage and Part D Advance Notice; Medicare.gov — Before using the Medicare Prescription Payment Plan; Medicare.gov — What pharmacies can I use?.
